murinemonoclonal antibody specific human αβ cell receptor investigational new drug development tolera therapeutics inc clinical stage investigational drug safety efficacy currently focus phase clinical trial renal transplant granted orphan drug status us food drug administration treatment recent onset immunemediated type diabetes prophylaxis acute rejection solid organ transplantationwhen numerous agents currently investigation capable modulating cells currently used agents include antithymocyte globulinatg alemtuzumab affect cells also capable modulating many aspects immune system often resulting longterm broad spectrum immune antibodies specific teplizumab show increased specificity cells compared atg alemtuzumab still associated infection cytokine release syndrome targeting αβ cells may reduce issues two mechanisms first infections expectedby reduced preservation γδ shown play important role controlling viruses cytomegalovirus often observed antibody treated patients second reductions cytokine release expectedby targeting αβ tcr unlike proteins αβ tcr contains none immunoreceptor tyrosinebased activation motifs itams required cell activationcitation needed shown vitro models specifically modulate αβ cells incubation peripheral blood monocytes pbmc triggers rapid modulation cell needed importantly occurs without cell proliferation cytokine induction examination ability modulate cells humanized mouse model confirmed vitro results also suggested cell modulating capability drug occurred nondepletional targeting αβ cells antibodies tested numerous experimental models disease data suggests models multiple sclerosis experimental autoimmune type diabetes nonobese diabetic antiαβ tcr antibody therapy ameliorate disease symptoms progressionverification needed precise mechanism occurs remains defined however likely involve induction operational tolerancecitation needed murine igm antibody